Selskabsmeddelelse24.5.2025, 10.40Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis
Pressemeddelelse19.5.2025, 06.30Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2
Pressemeddelelse21.1.2025, 07.00Lipidor announces half of patients enrolled in ongoing Phase III study
Pressemeddelelse20.11.2024, 07.00Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025"
Pressemeddelelse24.9.2024, 16.30Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis
Pressemeddelelse20.8.2024, 11.50Lipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan
Selskabsmeddelelse1.7.2024, 06.15Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue
Selskabsmeddelelse25.6.2024, 19.57Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants